Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05542849 · ClinicalTrials.gov registry record · Phase 4
The Efficacy and Tolerability of Acarbose in Healthy Individuals
A Phase 4 study, sponsored by AgelessRx.
- Completed
- Registry status
- Phase 4
- Development phase
- 15
- Enrollment target
NCT05542849 is a Phase 4 study that has completed, run by AgelessRx. The registered enrollment target is 15 participants.
The verdict
NCT05542849, a Phase 4 study, has completed, sponsored by AgelessRx.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 15 participants
- Enrollment target
Study Summary
A Prospective Trial for Acarbose in Healthy Individuals Assessing Safety and Efficacy in Reducing Glucose Spikes After Carbohydrate Consumption.
Interventions
- DRUG Acarbose Tablets 50mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2022-08-10 |
| Est. Completion | 2022-10-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05542849
The ClinicalTrials.gov registry entry for NCT05542849 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AgelessRx, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Acarbose Tablets 50mg is the first listed.
NCT05542849 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05542849 about?
NCT05542849 is a clinical study titled "The Efficacy and Tolerability of Acarbose in Healthy Individuals". A Prospective Trial for Acarbose in Healthy Individuals Assessing Safety and Efficacy in Reducing Glucose Spikes After Carbohydrate Consumption.
What is the current status of trial NCT05542849?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 15 participants. The study started on 2022-08-10. Estimated completion is 2022-10-05.
What interventions are being tested in trial NCT05542849?
The interventions under investigation include: Acarbose Tablets 50mg (DRUG).
Who is sponsoring clinical trial NCT05542849?
This trial is sponsored by AgelessRx, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.